We audited the marketing at Outcomes4Me
AI platform helping cancer patients navigate personalized care and clinical trials
This page was built using the same AI infrastructure we deploy for clients.
Month-to-month. Cancel anytime.
7K LinkedIn followers for a Series A healthtech with $37.7M funding suggests underinvestment in founder-led thought leadership and peer network expansion
No visible paid search campaigns targeting high-intent oncology keywords despite free platform model requiring user acquisition
Limited content strategy around NCCN guideline integration, competitive moat that should anchor organic and AEO visibility
AI-Forward Companies Trust MarketerHire
Plaid
MasterClass
Constant Contact
Netflix
Noom
TinuitiOutcomes4Me's Leadership
We mapped your current team to understand where MH-1 fits in.
MH-1 doesn't replace your team. It becomes your marketing team: dedicated humans + AI agents running execution at scale while you focus on product.
Here's Where You Stand
Series A healthtech with strong product-market validation but underdeveloped marketing infrastructure relative to funding and accolades
Platform likely ranks for oncology information queries but lacks content depth around genetic testing, clinical trial matching, and NCCN-backed guidance
MH-1: SEO module builds pillar content on genetic testing eligibility, clinical trial decision frameworks, and treatment pathway comparisons to capture high-intent patient searches
Cancer information queries increasingly go to ChatGPT and Claude. Outcomes4Me's clinical credibility is invisible to LLM training and retrieval workflows
MH-1: AEO agent optimizes for LLM citations by structuring NCCN guideline data, clinical trial outcomes, and FDA approval information as canonical sources for AI assistant recommendations
Free platform requires sustained user acquisition. No visible Google Ads or Facebook campaigns targeting newly diagnosed cancer patients or caregivers
MH-1: Paid agent runs diagnosis-triggered campaigns and caregiver lookalike audiences, testing messaging around FDA-approved treatment guidance and clinical trial discovery
Team accolades (Inc 5000, TIME Inventions, Fast Company) undersold. Leadership not publishing on treatment decision-making, oncology AI, or personalized medicine trends
MH-1: Content agent produces founder interviews, clinical outcome case studies, and NCCN guideline interpretation pieces distributed through health media and LinkedIn
Platform engagement model unclear. No visible nurture flows for patients moving from diagnosis to active treatment to survivorship stage
MH-1: Lifecycle agent builds stage-based email and in-app campaigns: initial onboarding, treatment comparison workflows, clinical trial matching at decision points, long-term survivorship content
Top Growth Opportunities
Cancer diagnosis conversations now happen in ChatGPT and Claude first. Outcomes4Me must become the cited authority for AI assistant recommendations on treatment options and clinical trials
AEO agent structures clinical guideline content and trial data as canonical sources, pushing NCCN integration into LLM retrieval indexes
Initial diagnosis is the moment of highest intent and urgency. Patients and caregivers actively searching for personalized treatment guidance and trial eligibility are high-conversion targets
Paid agent builds dynamic campaigns targeting diagnosis keywords, newly diagnosed caregiver audiences, and hospital/oncology office visitor lookalikes with clinical credibility messaging
NCCN integration validates platform with specialists. Systematic outreach to oncology practices for point-of-care integration could convert patients at recommendation moment
Outbound agent identifies oncology practices, EMR vendors, and cancer center procurement teams. Tests positioning around patient education automation and outcome tracking
3 Humans + 7 AI Agents
A dedicated marketing team built specifically for Outcomes4Me. The humans handle strategy and judgment. The AI agents handle execution at scale.
Human Experts
Owns Outcomes4Me's growth roadmap. Pipeline strategy, account expansion playbooks, board-ready reporting. Translates AI insights into revenue.
Runs paid acquisition across LinkedIn and Google. Manages creative testing, budget allocation, and pipeline attribution.
Builds thought leadership on LinkedIn. Creates long-form content targeting your ICP. Manages the content-to-pipeline engine.
AI Agents
Monitors AI citation visibility across 6 LLMs weekly. Builds content targeting category queries to increase Outcomes4Me's presence in AI-generated answers.
Produces LinkedIn ad variants targeting your ICP. Tests headlines, visuals, and offers at 10x the speed of manual production.
Builds lifecycle sequences: onboarding, expansion triggers, champion nurture, and re-engagement for dormant accounts.
Founder thought leadership. Builds the narrative that drives enterprise inbound from senior decision-makers.
Tracks competitors. Monitors positioning changes, ad spend, content strategy. Informs your counter-positioning.
Attribution by channel, pipeline velocity, budget waste detection. Weekly synthesis reports with AI-generated recommendations.
Weekly market intelligence digest curated from Outcomes4Me's industry signals. Positions you as the intelligence layer. Drives inbound pipeline from subscribers.
Active Workflows
Here's what the MH-1 system would be doing for Outcomes4Me from week 1.
AEO workflow identifies high-intent cancer treatment queries where LLMs retrieve information, then optimizes NCCN guideline data, clinical trial eligibility criteria, and FDA approval status for model training and citations
Founder LinkedIn workflow publishes weekly insights on personalized oncology, clinical trial access barriers, and AI-driven treatment guidance. Seeds peer engagement with oncologists, researchers, and health policy figures
Paid ad workflow runs diagnosis-triggered campaigns and caregiver lookalike audiences on Google and Facebook, testing messaging around personalized treatment options, clinical trial matching, and genetic testing guidance
Lifecycle workflow builds stage-based automation: initial onboarding for newly diagnosed patients, treatment comparison and trial matching during active care, survivorship planning and genetic risk content post-treatment
Competitive watch workflow monitors patient education platforms, AI health chatbots, clinical trial matching services, and oncology-focused health media. Flags content gaps Outcomes4Me can own
Pipeline intelligence workflow tracks oncology practice adoption signals, health system EMR partnerships, and investor activity in precision medicine. Identifies high-value pilot and partnership opportunities
Traditional Marketing vs. MH-1
Traditional Approach
MH-1 System
Audit. Sprint. Optimize.
3 phases. Real output every 2 weeks. You see results, not decks.
AI Audit + Growth Roadmap
Full diagnostic of Outcomes4Me's marketing infrastructure: SEO, AEO visibility, paid, content, lifecycle. Prioritized roadmap tied to pipeline metrics. Delivered in 7 days.
Sprint-Based Execution
2-week sprint cycles. Real campaigns, not presentations. Each sprint ships measurable output across your priority channels.
Compounding Intelligence
AI agents monitor your channels 24/7. They catch budget waste, detect creative fatigue, track AI citation changes, and run A/B experiments autonomously. Week 12 is measurably better than week 1.
AI Marketing Operating System
3 elite humans + AI agents operating your growth system
Output multiplier: ~10x output at a fraction of the cost. The system gets smarter every week.
Month-to-month. Cancel anytime.
Common Questions
How does MH-1 differ from a marketing agency?
MH-1 pairs 3 elite human marketers with 7 AI agents. The humans handle strategy, creative direction, and judgment calls. The AI agents handle execution at scale: generating ad variants, monitoring competitors, building email sequences, tracking citations across LLMs, running A/B experiments autonomously. You get the quality of a senior marketing team with the output volume of a 15-person department.
What kind of results can we expect in the first 90 days?
First 90 days focus on three parallel tracks. AEO identifies the oncology and clinical trial queries where LLMs currently provide generic information, then optimizes Outcomes4Me's clinical credibility as the cited source. Paid agents launch diagnosis-triggered and caregiver audience campaigns to test messaging and CAC. Content and LinkedIn agents publish founder perspectives on AI in cancer care and NCCN integration impact, seeding organic reach and positioning for partnership conversations with oncology practices.
How does AEO help Outcomes4Me compete with ChatGPT for cancer guidance questions
When patients ask ChatGPT or Claude about treatment options, clinical trials, or genetic testing, those models need reliable sources. AEO optimizes Outcomes4Me's NCCN-integrated guideline data, FDA approval information, and trial matching capability as canonical sources that LLMs cite. This drives both direct traffic and AI-mediated awareness among newly diagnosed patients seeking credible, personalized guidance.
Can we cancel anytime?
Yes. MH-1 is month-to-month with no long-term contracts. We earn your business every sprint. That said, compounding effects kick in around month 3 as the AI agents accumulate data and the system learns what works for Outcomes4Me specifically.
How is this page personalized for Outcomes4Me?
This page was researched, audited, and generated using the same AI infrastructure we deploy for clients. The channel scores, team mapping, growth opportunities, and recommended agents are all based on real analysis of Outcomes4Me's current marketing. This is a live demo of MH-1's capabilities.
Become the clinical AI authority cancer patients and doctors ask first
The system gets smarter every cycle. Let's talk about building it for Outcomes4Me.
Book a Strategy CallMonth-to-month. Cancel anytime.